 |
JOURNAL TOOLS |
| eTOC |
| To subscribe PROMO |
| Submit an article |
| Recommend to your librarian |
ARTICLE TOOLS |
| Reprints |
| Cite this article as |
YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
REVIEWS Free
Minerva Anestesiologica 2015 November;81(11):1229-43
Copyright © 2015 EDIZIONI MINERVA MEDICA
language: English
Periprocedural management of antithrombotic therapy and open issues in cancer patients
Cuomo A. 1, Cascella M. 1, Bifulco F. 1, Marracino M. 1, Di Minno G. 2, Cerbone A. M. 2 ✉
1 Division of Anesthesia, Intensive Care and Pain Therapy Unit, Istituto Nazionale Tumori “Fondazione G. Pascale” - IRCCS, Naples, Italy; 2 Department of Clinical Medicine and Surgery, Reference Center for Hemorrhagic and Thrombotic Diseases, Federico II University, Naples, Italy
Perioperative management of patients who are receiving anticoagulant or antiplatelet drugs and require surgical or invasive procedure is a dilemma for clinicians. The discontinuation exposes the patient to an exceedingly high risk of thromboembolism while there is an exceedingly high bleeding risk if antithrombotic therapy is continued, strictly related to the type of surgery. This complex management is based on the assessment of thromboembolic and bleeding risk. In this review we analyze the strategies to optimize the perioperative use of antithrombotic drugs with special attention to new oral anticoagulant drugs, also in cancer patients.